The Latest Breaking News from Neffy

First Needle-Free Epinephrine for Anaphylaxis Enters Real-World Clinical Use, Transforming Emergency Treatment for 32 Million Americans with Food Allergies

Neffy (epinephrine nasal spray), approved by the FDA in August 2024, is now in real-world clinical use as the first needle-free treatment for anaphylaxis. With summer outdoor activities creating an elevated allergy risk, here is why this device-free option is transforming emergency care for millions.

Medical Daily · Jun 15

ARS Pharmaceuticals Q1 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anaphylaxis. Co-founder

MarketBeat · May 15

What is Neffy? FDA approves first nasal spray to treat severe allergies

Neffy, the first single-dose nasal spray approved to treat severe allergies, will hit the market in a matter of weeks

The Independent UK · Aug 14, 2024